LEXINGTON, Mass. (AP) _ Dicerna Pharmaceuticals Inc. (DRNA) on Thursday reported a loss of $21.8 million in its third quarter.

On a per-share basis, the Lexington, Massachusetts-based company said it had a loss of 29 cents.

The results fell short of Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of 17 cents per share.

The biopharmaceutical company posted revenue of $48.9 million in the period, which also missed Street forecasts. Five analysts surveyed by Zacks expected $55.7 million.

Dicerna Pharmaceuticals shares have climbed 4% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $22.94, a rise of 34% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on DRNA at https://www.zacks.com/ap/DRNA

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News